Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3522187 | 0.83 | MAPK14 (0.48) | MAPK14KDM4EHPGDNPSR1LMNA | |
| SCHEMBL4487174 | 0.83 | MAPK14 (0.54) | MAPK14KDM4EP2RX7BRAFPDGFRB | |
| SCHEMBL3520013 | 0.82 | MAPT (0.53) | MAPK14KDM4EHPGDNPSR1LMNA | |
| SCHEMBL3523270 | 0.78 | MAPK14 (0.49) | MAPK14KDM4EHPGDNPSR1PDGFRB | |
| SCHEMBL3521065 | 0.77 | MAPK14 (0.52) | MAPK14KDM4EHPGDNPSR1LMNA | |
| SCHEMBL3524048 | 0.76 | KDM4E (0.48) | MAPK14KDM4EHPGDNPSR1LMNA | |
| SCHEMBL3521808 | 0.73 | MAPK14 (0.44) | MAPK14KDM4EHPGDNPSR1LMNA | |
| SCHEMBL3521076 | 0.73 | MAPT (0.49) | MAPK14KDM4EHPGDNPSR1LMNA | |
| SCHEMBL3526877 | 0.73 | HPGD (0.57) | MAPK14KDM4EHPGDNPSR1MAPT | |
| SCHEMBL3523859 | 0.73 | MAPK14 (0.57) | MAPK14KDM4EHPGDNPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795271-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | PFIZER INC | 2009-12-10 | — | — | US | disclosed |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | PHARMACIA CORPORATION (US) | 2007-07-19 | — | — | US | disclosed |
| US-7183287-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040242608-A1 | Substituted pyrimidinones | PHARMACIA LLC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MAPK14 38/4885KDM4E 3806/4885HPGD 418/4885 |
| US-20040242608-A1 | Substituted pyrimidinones | MAPK1, MAPK7, MAP3K8 | MAPK14 29/4885KDM4E 3935/4885HPGD 442/4885 |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MAPK14 38/4885KDM4E 3806/4885HPGD 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.